|
|
|
|
|
|
|
|
|
|
pharma news
The European Medicines Agency (EMA) has granted Orphan Drug Designation to Debiopharm International‘s Debio 1143 for treatment of ovarian cancer.
Wednesday, December 09, 2015
European Medicines Agency (EMA) grants Orphan Drug Designation for Debio 1143 (ovarian cancer)
pharma news
The European Medicines Agency (EMA) has granted Orphan Drug Designation to Debiopharm International‘s Debio 1143 for treatment of ovarian cancer.
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.